TY  - JOUR 
AU  - Mateos Manteca, María Victoria
AU  - Gutiérrez Gutiérrez, Norma Carmen
AU  - Martín-Ramos, María-Luisa
AU  - Lourenço Paiva, Bruno
AU  - Montalbán, María-Angeles
AU  - Oriol, Albert
AU  - Martínez-López, Joaquín
AU  - Teruel, Ana-Isabel
AU  - Bengoechea, Enrique
AU  - Martín, Alejandro
AU  - Díaz-Mediavilla, Joaquín
AU  - De Arriba, Felipe
AU  - Palomera, Luis
AU  - Hernández, José-Mariano
AU  - Sureda, Anna
AU  - Bargay, Joan
AU  - Peñalver, Francisco-Javier
AU  - Ribera Santasusana, Josép María
AU  - Martín-Mateos, María-Luisa
AU  - Fernández, Manuela
AU  - García Sanz, Ramón
AU  - Vidriales Vicente, María Belén
AU  - Bladé, Joan
AU  - Lahuerta, Juan-José
AU  - San Miguel Izquierdo, Jesús Fernando
PY  - 2011
SN  - 0006-4971
UR  - http://hdl.handle.net/10366/154309
AB  - [EN]Cytogenetic abnormalities (CAs) such as t(4;14), t(14;16) or del(17p), and nonhyperdiploidy are associated with poor prognosis in multiple myeloma. We evaluated the influence of CAs by FISH and DNA ploidy by flow cytometry on response and survival...
LA  - eng
PB  - American Society of Hematology
KW  - Mieloma múltiple
KW  - Chromosome Aberrations
KW  - Aged
KW  - Boronic Acids
KW  - Induction Chemotherapy
KW  - DNA
KW  - Drug Administration Schedule
KW  - Humans
KW  - Pyrazines
KW  - Algorithms
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Prognosis
KW  - Multiple Myeloma
KW  - Maintenance Chemotherapy
KW  - Time Factors
KW  - Treatment Outcome
KW  - Ploidies
TI  - Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance
DO  - 10.1182/blood-2011-04-345801
T2  - Blood
VL  - 118
M2  - 4547
ER  -